Point72 Asset Management L.P. Lowers Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Point72 Asset Management L.P. trimmed its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 55.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 193,600 shares of the company’s stock after selling 244,100 shares during the quarter. Point72 Asset Management L.P.’s holdings in Dianthus Therapeutics were worth $4,220,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics in the 4th quarter valued at about $26,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $35,000. BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth about $59,000. Finally, AlphaQuest LLC raised its position in shares of Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock worth $91,000 after acquiring an additional 3,072 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DNTH shares. Robert W. Baird cut their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, Guggenheim restated a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $53.00.

Dianthus Therapeutics Stock Performance

DNTH opened at $19.27 on Tuesday. The business’s fifty day moving average is $19.34 and its two-hundred day moving average is $22.01. The company has a market cap of $619.72 million, a price-to-earnings ratio of -7.71 and a beta of 1.48. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.